Breaking News Instant updates and real-time market news.

CRIS

Curis

$3.37

0.05 (1.51%)

, RHHBY

Roche

$28.02

0.6 (2.19%)

07:16
11/28/16
11/28
07:16
11/28/16
07:16

Curis announces full approval of Roche drug Erivedge in EU

Curis (CRIS) announced that the European Medicines Agency's, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has granted full approval to Erivedge for the treatment of adult patients with symptomatic metastatic basal cell carcinoma, or BCC, or locally advanced BCC inappropriate for surgery or radiotherapy. Erivedge is also approved in the U.S. for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. Erivedge was developed and is marketed by Roche (RHHBY) and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech.

CRIS

Curis

$3.37

0.05 (1.51%)

RHHBY

Roche

$28.02

0.6 (2.19%)

  • 29

    Nov

  • 03

    Dec

CRIS Curis
$3.37

0.05 (1.51%)

03/01/16
RHCO
03/01/16
INITIATION
Target $3
RHCO
Buy
Curis initiated with a Buy at SunTrust
Target $3.
05/05/16
COWN
05/05/16
INITIATION
COWN
Outperform
Curis coverage assumed with an Outperform at Cowen
RHHBY Roche
$28.02

0.6 (2.19%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.

TODAY'S FREE FLY STORIES

SCM

Stellus Capital

$13.63

-0.02 (-0.15%)

07:46
09/25/17
09/25
07:46
09/25/17
07:46
Initiation
Stellus Capital initiated  »

Stellus Capital initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$19.73

0.42 (2.18%)

07:46
09/25/17
09/25
07:46
09/25/17
07:46
Periodicals
KKR raises offer for Australia's Pepper Group to $543M, Reuters says »

KKR has raised its bid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSR

Versar

$0.48

0.033 (7.33%)

07:44
09/25/17
09/25
07:44
09/25/17
07:44
Hot Stocks
Breaking Hot Stocks news story on Versar »

Versar trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$88.27

2.22 (2.58%)

07:44
09/25/17
09/25
07:44
09/25/17
07:44
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$15.64

0.62 (4.13%)

07:42
09/25/17
09/25
07:42
09/25/17
07:42
Recommendations
Pure Storage analyst commentary  »

Pure Storage price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

PGR

Progressive

$47.98

0.3 (0.63%)

07:41
09/25/17
09/25
07:41
09/25/17
07:41
Recommendations
Progressive analyst commentary  »

Progressive outlook has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPC

Genuine Parts

$87.98

1.63 (1.89%)

07:41
09/25/17
09/25
07:41
09/25/17
07:41
Conference/Events
Genuine Parts to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 19

    Oct

  • 30

    Oct

TFX

Teleflex

$241.77

4.71 (1.99%)

07:41
09/25/17
09/25
07:41
09/25/17
07:41
Recommendations
Teleflex analyst commentary  »

Teleflex price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

BAS

Basic Energy

$17.24

-0.34 (-1.93%)

07:41
09/25/17
09/25
07:41
09/25/17
07:41
Recommendations
Basic Energy analyst commentary  »

Basic Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 16

    May

EONGY

E.ON AG

$11.19

0.2 (1.82%)

07:38
09/25/17
09/25
07:38
09/25/17
07:38
Periodicals
E.ON CFO defends plan to sell Uniper stake to Fortum, Reuters reports »

E.ON CFO Marc Spieker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$204.65

1.99 (0.98%)

07:36
09/25/17
09/25
07:36
09/25/17
07:36
Hot Stocks
Allergan announces resignation of CFO Tessa Hilado »

Allergan announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

WBC

Wabco

$150.14

0.95 (0.64%)

07:36
09/25/17
09/25
07:36
09/25/17
07:36
Initiation
Wabco initiated  »

Wabco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

FNV

Franco-Nevada

$79.32

0.4 (0.51%)

07:35
09/25/17
09/25
07:35
09/25/17
07:35
Downgrade
Franco-Nevada rating change  »

Franco-Nevada downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTN

Palatin

$0.66

0.06 (10.00%)

07:35
09/25/17
09/25
07:35
09/25/17
07:35
Earnings
Palatin reports Q4 EPS 7c, may not compare to consensus (2c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AAPL

Apple

$151.89

-1.5 (-0.98%)

, GE

General Electric

$24.87

0.12 (0.48%)

07:35
09/25/17
09/25
07:35
09/25/17
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

AAPL

Apple

$151.89

-1.5 (-0.98%)

GE

General Electric

$24.87

0.12 (0.48%)

ORCL

Oracle

$48.16

0.19 (0.40%)

M

Macy's

$21.53

0.37 (1.75%)

COP

ConocoPhillips

$49.08

0.39 (0.80%)

FCAU

Fiat Chrysler

$17.95

0.58 (3.34%)

WETF

WisdomTree

$9.25

0.23 (2.55%)

KBH

KB Home

$20.88

0.1 (0.48%)

MDR

McDermott

$7.01

0.1 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 02

    Oct

  • 22

    Oct

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

07:33
09/25/17
09/25
07:33
09/25/17
07:33
Hot Stocks
Spark Therapeutics appoints Dr. Federico Mingozzi as Chief Scientific Officer »

Spark Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

AGN

Allergan

$204.65

1.99 (0.98%)

07:32
09/25/17
09/25
07:32
09/25/17
07:32
Hot Stocks
Allergan announces new $2B share repurchase plan, affirms guidance »

Allergan announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ECA

Encana

$11.25

-0.05 (-0.44%)

07:31
09/25/17
09/25
07:31
09/25/17
07:31
Recommendations
Encana analyst commentary  »

Encana price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$204.65

1.99 (0.98%)

07:30
09/25/17
09/25
07:30
09/25/17
07:30
Hot Stocks
Breaking Hot Stocks news story on Allergan »

Allergan announces new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EXAS

Exact Sciences

$45.96

0.96 (2.13%)

, ROK

Rockwell Automation

$177.55

0.22 (0.12%)

07:30
09/25/17
09/25
07:30
09/25/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

EXAS

Exact Sciences

$45.96

0.96 (2.13%)

ROK

Rockwell Automation

$177.55

0.22 (0.12%)

DVA

DaVita

$57.49

-3.77 (-6.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

NTDOY

Nintendo

$45.62

-0.98 (-2.10%)

, GOOG

Alphabet

$928.53

-3.92 (-0.42%)

07:29
09/25/17
09/25
07:29
09/25/17
07:29
Periodicals
Nintendo adds two-factor authentication for accounts, the Verge says »

Nintendo (NTDOY) users…

NTDOY

Nintendo

$45.62

-0.98 (-2.10%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

EGO

Eldorado Gold

$2.26

0.02 (0.89%)

07:29
09/25/17
09/25
07:29
09/25/17
07:29
Upgrade
Eldorado Gold rating change  »

Eldorado Gold upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

APRN

Blue Apron

$5.19

-0.04 (-0.76%)

07:28
09/25/17
09/25
07:28
09/25/17
07:28
Initiation
Blue Apron initiated  »

Blue Apron initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$188.30

0.39 (0.21%)

07:27
09/25/17
09/25
07:27
09/25/17
07:27
Recommendations
Thermo Fisher analyst commentary  »

Thermo Fisher price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$51.60

4.8 (10.26%)

07:27
09/25/17
09/25
07:27
09/25/17
07:27
Recommendations
Cubic analyst commentary  »

Cubic price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.